<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00315003</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6132</org_study_id>
    <secondary_id>HMR3647B/3002</secondary_id>
    <nct_id>NCT00315003</nct_id>
  </id_info>
  <brief_title>TELI COM - Telithromycin in Children With Otitis Media</brief_title>
  <official_title>Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 5 Days Azithromycin 10 mg/kg od Followed by 5 mg/kg od for 4 Days, in Children With Acute Otitis Media</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      This is a multinational, randomized (1:1), double-blind, double-dummy, comparative, 2-&#xD;
      treatmentgroup study in children (age range: ≥6 months and &lt;72 months [&lt; 6 years of age])&#xD;
      with AOM.Subjects will be randomized to receive either telithromycin (50 mg/mL) oral&#xD;
      suspension 25 mg/kgonce daily for 5 days or azithromycin (40 mg/mL) oral suspension (10 mg/kg&#xD;
      once on Day 1, followed by 5 mg/kg once daily on Days 2-5, not to exceed 500 mg onDay 1 and&#xD;
      250 mg/day from Days 2 - 5. Matching placebo suspensions for telithromycin and azithromycin&#xD;
      will also be dispensed to provide blinding for the different treatment regimens.Assessments&#xD;
      and reporting of safety will be carried out at all visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Pediatric development program terminated by sponsor&#xD;
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy variables will be time to symptom resolution (TSR) and clinical cure at theposttherapy/TOC Visit 3.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) reported by subjects, their parents/legally authorized representative, orobserved by the investigators will be recorded throughout the study.</measure>
  </secondary_outcome>
  <enrollment>1500</enrollment>
  <condition>Otitis Media, Suppurative</condition>
  <condition>Otitis Media, Purulent</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects meeting all of the following criteria will be considered for enrollment into the&#xD;
        study:&#xD;
&#xD;
          -  Subjects ≥6 months and &lt;72 months (&lt; 6 years) of age;&#xD;
&#xD;
          -  Recent (within the last 72 hours) and rapid onset of AOM symptoms and signs;&#xD;
&#xD;
          -  The presence of MEF on otoscopy indicated by a bulging tympanic membrane;&#xD;
&#xD;
          -  Otalgia or ear tugging or touching within the last 24 hours that interferes with or&#xD;
             precludes normal activity or sleep;&#xD;
&#xD;
          -  At least 1 of the following clinical findings not specific to AOM: fever, vomiting,&#xD;
             diarrhea, anorexia, sleep disturbance, or irritability;&#xD;
&#xD;
          -  Caregiver-reported AOM symptoms sufficient for entry according to protocol criteria.&#xD;
&#xD;
          -  Caregiver-reported AOM symptoms diary&#xD;
&#xD;
          -  Tympanometry exhibiting:&#xD;
&#xD;
               -  Type B curve or positive pressure peak curves.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects presenting with any of the following will not be included in the study:&#xD;
&#xD;
          -  Uncertain diagnosis of AOM or mild to moderate symptoms and signs of AOM that would&#xD;
             make the subject a candidate for observation and analgesic therapy with observation&#xD;
             for 2-3 days.&#xD;
&#xD;
          -  Otorrhea or tympanostomy tube present in the ear to be evaluated;&#xD;
&#xD;
          -  Otitis externa;&#xD;
&#xD;
          -  Down syndrome, cleft palate, craniofacial disorders, cystic fibrosis/mucoviscidosis,&#xD;
             immotile cilia syndrome, congenital immunodeficiency or acquired immunodeficiency&#xD;
             syndrome with &lt;25% CD4 count or requiring prophylaxis for Pneumocystis jiroveci&#xD;
             (carinii) or requiring treatment for an opportunistic infection;&#xD;
&#xD;
          -  Known congenital long QT syndrome;&#xD;
&#xD;
          -  Known or suspected uncorrected hypokalemia (≤3 mmol/L [mEq/L]), hypomagnesemia,&#xD;
             bradycardia (&lt;50 bpm);&#xD;
&#xD;
          -  Myasthenia gravis;&#xD;
&#xD;
          -  Known impaired renal function, as shown by creatinine clearance ≤25 mL/min;&#xD;
&#xD;
          -  History of hypersensitivity or intolerance to macrolides or azithromycin;&#xD;
&#xD;
          -  Previous enrollment in this study or previous treatment with telithromycin;&#xD;
&#xD;
          -  Children of the investigator or subinvestigator, research assistant, pharmacist, study&#xD;
             coordinator, other staff, or relative thereof directly involved in the conduct of the&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1642</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05677-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Providencia</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Santafe de Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>San José</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Praha</city>
        <zip>160 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Santo-Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Israel</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Czech Republic</country>
    <country>Dominican Republic</country>
    <country>Guatemala</country>
    <country>Israel</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>April 13, 2006</study_first_submitted>
  <study_first_submitted_qc>April 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2006</study_first_posted>
  <last_update_submitted>April 2, 2009</last_update_submitted>
  <last_update_submitted_qc>April 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Otitis Media</keyword>
  <keyword>Suppurative</keyword>
  <keyword>Purulent</keyword>
  <keyword>Ketolide</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Telithromycin</keyword>
  <keyword>Controlled Clinical Trials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suppuration</mesh_term>
    <mesh_term>Otitis Media, Suppurative</mesh_term>
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Telithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

